Physician profile
Robert C Mcdonough
NPI 1720074503
$5,442.28
in general payments reported to CMS, 2019-2025
18 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $255 · 2021: $413 · 2022: $1,119 · 2023: $726 · 2024: $485 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666 · Travel and Lodging: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.16 |
| Travel and Lodging | $784.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,606.27 | 2019-2025 | Ams 700, Advance Xp |
| Medtronic, INC. | $954.68 | 2022-2025 | Altaviva |
| Coloplast Corp | $379.86 | 2019-2025 | Titan |
| Endo Pharmaceuticals INC. | $348.29 | 2019-2023 | Xiaflex, Aveed, Edex |
| Karl Storz Endoscopy-America | $197.58 | 2022-2023 | Flex-X |
| Axonics, INC. | $167.97 | 2021 | |
| Astellas Pharma US INC | $135.26 | 2019 | |
| Myriad Genetic Laboratories, INC. | $118.73 | 2022 | |
| Abbvie INC. | $104.23 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $75.51 | 2024-2025 | Gemtesa |
| Calyxo, INC. | $72.42 | 2024-2025 | Cvac Aspiration System |
| Endo USA, INC. | $72.23 | 2024-2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $65.16 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Photocure INC | $53.26 | 2019 | |
| Profound Medical Corp. | $27.80 | 2023 | Tulsa-Pro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26.69 | 2025 | |
| Ferring Pharmaceuticals INC. | $19.89 | 2025 | Adstiladrin |
| Tolmar, INC. | $16.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.